MTOR and non-small cell lung carcinoma: A total of 40 patients with EGFR-mutant NSCLC who had cancer progression on osimertinib were assigned to two groups, and received osimertinib in combination with either alisertib, an aurora kinase inhibitor, or sapanisertib, an mTOR inhibitor.